Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > Interference

<< Previous

Bullboard Posts

Next >>

Comment by QualityTeston Jan 17, 2022 9:53am

226 Views

Post# 34323908

RE:RE:RE:RE:RE:Interference

Priceless,

Someone on the Agora board pointed out that one of the PIII advisory council members has been on CNN numerous times dicussing Covid. That's exactly the person we need to make up for IR's weakness. All we need is for him to be on a national US news station and be able to say that we have data proving RVX's effectiveness and we are off to the races.

But WTF is happening with dosing? 70k cases a day in Brazil and we don't have one single patient dosed when we were supposedly starting screening at the beginning on Jan? Lol- at least IR has confirmed we can expect an update in the coming weeks and, theoritcally, that NR saying dosing has commenced could come any day now.

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale